postural orthostatic tachycardia syndrome
Excessive sinus tachycardia on standing, without OH. A syndrome, not one disease: the overlapping mechanisms are hypovolaemia, peripheral autonomic denervation (poor vasoconstriction → compensatory tachycardia), hyperadrenergic tone and deconditioning (small LV, low stroke volume). Most of the tachycardia is compensatory, so treatment restores volume and venous return first. High-dose beta-blockade lowers HR without improving symptoms. Subtyping by mechanism isn’t recommended at diagnosis (strong).
diagnosis
CCS criteria (strong):
- Sustained HR rise ≥30 bpm within 10 min of standing (age 12–19: ≥40 bpm and standing HR ≥100). Measure after ≥5 min supine. Confirm on ≥2 readings ≥1 min apart after the first minute. With a supine HR <60, count from 60 (standing HR ≥90 in adults)
- No OH (systolic drop >20 mmHg or diastolic >10 mmHg within 3 min). Transient initial OH (<1 min) doesn’t exclude POTS
- Predominant orthostatic symptoms that improve lying down, lasting ≥3 months. Usually women aged 13–40 (HRS: prevalence ~0.2%, onset mostly 15–25, >75% female), often after infection, surgery or pregnancy
- Not POTS: postural tachycardia of other cause (hypovolaemia, anaemia, hyperthyroidism, adrenal insufficiency, phaeochromocytoma, drugs, bed rest) → treat the cause. Symptoms without tachycardia → PSWT. Tachycardia without symptoms → reassure. IST = resting sinus HR >100 (24-h mean >90), triggered by any physiological or emotional stress rather than posture → ivabradine 5–7.5 mg BID (HRS IIa); beta-blockers often ineffective; no sinus node ablation (HRS III)
- “POTS plus” = POTS with debilitating non-cardiovascular symptoms (gastroparesis, neurogenic bladder, chronic pain) or a comorbidity (hypermobile EDS, mast cell activation, ME/CFS, autoimmune disease) → specialist care
workup
History (triggers, salt and fluid intake, functional capacity, autonomic review of systems, drugs), exam, standing test, 12-lead ECG. Bloods: CBC, electrolytes, creatinine/urea, ferritin, TSH, morning cortisol. No routine echo, ambulatory monitoring, tilt, autonomic testing, catecholamines or neuroimaging (unless structural disease, a non-sinus arrhythmia or a focal deficit is suspected).
treatment
No drug is approved for POTS in Canada. Non-drug measures are always first line; add drugs for disabling symptoms or when non-drug measures fail. Multidisciplinary team (physio, exercise physiology, dietitian, psychology) suggested (weak).
| Step | Treatment | Strength |
|---|---|---|
| 1 | withdraw aggravating drugs (stimulants, SNRIs, TCAs, α-blockers, high-dose beta-blockers) | strong |
| 1 | water ≥3 L/day + NaCl 10 g/day (target 24-h urine Na⁺ >170 mmol); sleep head-up (>10°) | strong |
| 1 | exercise training: start recumbent (rowing, recumbent bike, swimming), ≥30 min ≥4 days/week; benefit after 4–6 weeks | strong |
| 1 | waist-high compression (20–30 mmHg, increase as tolerated) or abdominal binder | weak |
| 2 | midodrine 2.5–15 mg up to TID, before upright activity, never supine; best with low-BP phenotype | strong |
| 2 | propranolol 10–20 mg up to QID. Low-dose non-selective: higher or long-acting doses lower HR but don’t help symptoms, and can worsen fatigue and exercise tolerance | strong |
| 2 | pyridostigmine 30–60 mg TID (diarrhoea; useful if constipated) | weak |
| 2 | fludrocortisone 0.1–0.3 mg daily (hypokalaemia; avoid in migraine) | weak |
| 2 | ivabradine 2.5–7.5 mg BID (if beta-blocker fails or isn’t tolerated; teratogenic) | weak |
| 2 | clonidine or methyldopa for hyperadrenergic phenotype (standing SBP rise ≥10 mmHg, prominent palpitations, tremor, anxiety) | weak |
| rescue | IV NS 1–2 L over 1–2 h, occasionally | weak |
| against | regular long-term IV saline (line infection/thrombosis), sinus node ablation, Chiari decompression, jugular venoplasty | strong |
- HRS 2015 grades most of the same measures lower: exercise IIa; water 2–3 L + NaCl 10–12 g/day, fludrocortisone, pyridostigmine, midodrine, low-dose propranolol all IIb; IV saline up to 2 L for decompensation IIa; norepinephrine-reuptake inhibitors (e.g. SNRIs, atomoxetine) III — worsen symptoms
- Modafinil for fatigue/“brain fog” (may worsen tachycardia)
- Course: chronic, no known mortality, most improve over time
Prepared 2026-10-21. Not yet verified — check every number against the sources.